Navigation Links
HIVMA opposes The Gambia's unproven AIDS remedy

Leading HIV experts are alarmed that the government of The Gambia is encouraging citizens living with HIV to stop taking antiretroviral medications in order to try an unproven herbal remedy. The HIV Medicine Association (HIVMA) calls on President Yahya Jammeh to cease his unproven claims that the treatment "cures" AIDS.

Earlier this year, President Jammeh began applying his treatment to a handful of patients who had been doing well on antiretroviral therapy but stopped taking the drugs in order to qualify to receive his "cure."

HIVMA joins its colleagues in the International AIDS Society and the Society for AIDS in Africa in expressing great concern regarding this practice. "There currently is no cure for HIV/AIDS," said HIVMA Chair Daniel R. Kuritzkes, MD. "President Jammeh is giving people false hope, while at the same time making them stop treatment that has been demonstrated to save lives."

"Any treatment that claims to alleviate this devastating disease must be subjected to rigorous scientific scrutiny," he added. "A growing body of evidence from Africa shows the lifesaving effects of antiretroviral medicines for people living with HIV/AIDS. On the other hand, the remedy President Jammeh is promoting is untested. It is highly unethical to stop a proven therapy to try an unproven one. We are extremely concerned that President Jammeh would recklessly experiment with his people’s lives."

"We support the tireless efforts of African scientists, clinicians, and community health workers providing antiretroviral treatment to communities that are so deeply affected by this disease." Dr. Kuritzkes added. "We urge the government of the Gambia to support their efforts as well."

Dr. Kuritzkes concluded, "People around the world living with HIV/AIDS deserve safe, effective, and affordable treatment, regardless of the source. If President Jammeh’s remedy is as effective as he claims, it will stand up to examination. In the mean time, we urge patients receiving his unproven herbal remedy to resume taking their antiretroviral medications, which have a well-established track record of saving lives in Africa."
'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
2. Medical whistleblowers speak out
3. The evolutionary triumph of flower power
4. Bumblebees copy one another when contending with unfamiliar flowers
5. Analysis of flower genes reveals the fate of an ancient gene duplication
6. Gene therapy to lower blood pressure just enough
7. Long-sought flower-inducing molecule found
8. Divergent mating systems and parental conflict as a barrier to hybridization in flowering plants
9. Reducing antibiotic use lowers rates of drug-resistant bacteria
10. Recreating Flowers for Algernon with a happy ending
11. Overfishing may drive endangered seabird to rely upon lower quality food

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: